NasdaqGS:INSMBiotechs
Assessing Insmed (INSM) Valuation After Brinsupri Outperformance And Upgraded 2026 Revenue Guidance
Insmed (INSM) has been in focus after its fourth quarter and full year 2025 earnings, where strong revenue from ARIKAYCE and new drug BRINSUPRI contrasted with a wider net loss and ambitious 2026 sales guidance.
See our latest analysis for Insmed.
Insmed’s recent earnings and guidance have come alongside a sharp move in the share price, with a 10.86% 7 day share price return and 5.57% 30 day share price return partly offsetting a 21.10% 90 day share price decline. The 1 year total shareholder...